BRIEF published on 08/27/2024 at 13:05, 2 years ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 2 years ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 2 years ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 2 years 1 month ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 2 years 1 month ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 2 years 1 month ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 2 years 2 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 2 years 2 months ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 2 years 2 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 2 years 3 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 08/29/2026 at 05:15, 12 hours 10 minutes ago Norsemont Announces Restatement of Financial Statements
Published on 08/29/2026 at 03:20, 14 hours 5 minutes ago BEACN Announces Financial Results for the Second Quarter of 2026
Published on 08/29/2026 at 01:15, 16 hours 10 minutes ago Gamma Resources Announces Increase in Private Placement to $1,750,000 and Closing of First Tranche at $872,500
Published on 08/29/2026 at 01:00, 16 hours 25 minutes ago Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Published on 08/28/2026 at 23:00, 18 hours 25 minutes ago Guanajuato Silver Grants Stock Options to Officer
Published on 08/29/2026 at 04:05, 13 hours 19 minutes ago INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces
Published on 08/28/2026 at 20:49, 20 hours 35 minutes ago Publication pursuant to Article 5(1)(b) and (3) of Regulation (EU) No. 596/2014 and Article 2(2) and (3) of the Commission Delegated Regulation (EU) No. 2016/1052 - Final Announcement
Published on 08/28/2026 at 20:42, 20 hours 42 minutes ago Aroundtown SA: Release of a capital market information
Published on 08/28/2026 at 19:10, 22 hours 14 minutes ago Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Published on 08/28/2026 at 18:01, 23 hours 23 minutes ago CPI Europe announces unaudited results for the first half of 2026
